Copyright Reports & Markets. All rights reserved.

Global Component DTP Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Component DTP Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Two-component
    • 1.3.3 Multi-componen
  • 1.4 Market Analysis by Immunization Purpose
    • 1.4.1 Overview: Global Component DTP Vaccine Consumption Value by Immunization Purpose: 2021 Versus 2025 Versus 2032
    • 1.4.2 Primary Immunization Vaccine
    • 1.4.3 Booster Immunization Vaccine
  • 1.5 Market Analysis by User
    • 1.5.1 Overview: Global Component DTP Vaccine Consumption Value by User: 2021 Versus 2025 Versus 2032
    • 1.5.2 Below 12 Months
    • 1.5.3 Above 12 Months
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Component DTP Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospital
    • 1.6.3 Clinic
  • 1.7 Global Component DTP Vaccine Market Size & Forecast
    • 1.7.1 Global Component DTP Vaccine Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Component DTP Vaccine Sales Quantity (2021-2032)
    • 1.7.3 Global Component DTP Vaccine Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Sanofi Pasteur
    • 2.1.1 Sanofi Pasteur Details
    • 2.1.2 Sanofi Pasteur Major Business
    • 2.1.3 Sanofi Pasteur Component DTP Vaccine Product and Services
    • 2.1.4 Sanofi Pasteur Component DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Sanofi Pasteur Recent Developments/Updates
  • 2.2 GSK
    • 2.2.1 GSK Details
    • 2.2.2 GSK Major Business
    • 2.2.3 GSK Component DTP Vaccine Product and Services
    • 2.2.4 GSK Component DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 GSK Recent Developments/Updates
  • 2.3 KM Biologics
    • 2.3.1 KM Biologics Details
    • 2.3.2 KM Biologics Major Business
    • 2.3.3 KM Biologics Component DTP Vaccine Product and Services
    • 2.3.4 KM Biologics Component DTP Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 KM Biologics Recent Developments/Updates

3 Competitive Environment: Component DTP Vaccine by Manufacturer

  • 3.1 Global Component DTP Vaccine Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Component DTP Vaccine Revenue by Manufacturer (2021-2026)
  • 3.3 Global Component DTP Vaccine Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Component DTP Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Component DTP Vaccine Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Component DTP Vaccine Manufacturer Market Share in 2025
  • 3.5 Component DTP Vaccine Market: Overall Company Footprint Analysis
    • 3.5.1 Component DTP Vaccine Market: Region Footprint
    • 3.5.2 Component DTP Vaccine Market: Company Product Type Footprint
    • 3.5.3 Component DTP Vaccine Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Component DTP Vaccine Market Size by Region
    • 4.1.1 Global Component DTP Vaccine Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Component DTP Vaccine Consumption Value by Region (2021-2032)
    • 4.1.3 Global Component DTP Vaccine Average Price by Region (2021-2032)
  • 4.2 North America Component DTP Vaccine Consumption Value (2021-2032)
  • 4.3 Europe Component DTP Vaccine Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Component DTP Vaccine Consumption Value (2021-2032)
  • 4.5 South America Component DTP Vaccine Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Component DTP Vaccine Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Component DTP Vaccine Sales Quantity by Type (2021-2032)
  • 5.2 Global Component DTP Vaccine Consumption Value by Type (2021-2032)
  • 5.3 Global Component DTP Vaccine Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Component DTP Vaccine Sales Quantity by Application (2021-2032)
  • 6.2 Global Component DTP Vaccine Consumption Value by Application (2021-2032)
  • 6.3 Global Component DTP Vaccine Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Component DTP Vaccine Sales Quantity by Type (2021-2032)
  • 7.2 North America Component DTP Vaccine Sales Quantity by Application (2021-2032)
  • 7.3 North America Component DTP Vaccine Market Size by Country
    • 7.3.1 North America Component DTP Vaccine Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Component DTP Vaccine Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Component DTP Vaccine Sales Quantity by Type (2021-2032)
  • 8.2 Europe Component DTP Vaccine Sales Quantity by Application (2021-2032)
  • 8.3 Europe Component DTP Vaccine Market Size by Country
    • 8.3.1 Europe Component DTP Vaccine Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Component DTP Vaccine Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Component DTP Vaccine Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Component DTP Vaccine Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Component DTP Vaccine Market Size by Region
    • 9.3.1 Asia-Pacific Component DTP Vaccine Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Component DTP Vaccine Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Component DTP Vaccine Sales Quantity by Type (2021-2032)
  • 10.2 South America Component DTP Vaccine Sales Quantity by Application (2021-2032)
  • 10.3 South America Component DTP Vaccine Market Size by Country
    • 10.3.1 South America Component DTP Vaccine Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Component DTP Vaccine Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Component DTP Vaccine Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Component DTP Vaccine Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Component DTP Vaccine Market Size by Country
    • 11.3.1 Middle East & Africa Component DTP Vaccine Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Component DTP Vaccine Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Component DTP Vaccine Market Drivers
  • 12.2 Component DTP Vaccine Market Restraints
  • 12.3 Component DTP Vaccine Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Component DTP Vaccine and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Component DTP Vaccine
  • 13.3 Component DTP Vaccine Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Component DTP Vaccine Typical Distributors
  • 14.3 Component DTP Vaccine Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Component DTP Vaccine market size was valued at US$ 4742 million in 2025 and is forecast to a readjusted size of US$ 6014 million by 2032 with a CAGR of 3.4% during review period.
    In 2025, global Component DTP Vaccine production reached approximately 309 million doses, with an average global market price of around US$ 15 per square meter. Component DTP Vaccine (also known as Acellular DTP Vaccine, DTaP, or Component-based Diphtheria-Tetanus-Pertussis Vaccine) is a vaccine designed to prevent diphtheria, tetanus, and pertussis (whooping cough) by using purified antigen components rather than whole-cell bacterial components.
    The global Component DTP Vaccine (Acellular Diphtheria, Tetanus, and Pertussis Vaccine, DTaP) market is an important segment of the global pediatric vaccine industry, focusing on the prevention of diphtheria, tetanus, and pertussis through purified antigen components rather than whole-cell bacterial components. Compared with whole-cell DTP vaccines, Component DTP Vaccines use selected and purified pertussis antigens, such as pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbrial proteins (FIM), combined with diphtheria and tetanus toxoids to stimulate immune responses. Due to their improved safety profile, lower incidence of adverse reactions, and broad acceptance in developed immunization programs, Component DTP Vaccines have become the mainstream DTP vaccine type in many high-income markets, including North America, Europe, Japan, and other developed regions. The market is primarily driven by continued global childhood immunization programs, government vaccination initiatives, increasing demand for combination vaccines, replacement of older whole-cell vaccines, and improvements in vaccine coverage in emerging economies. Component DTP Vaccines are widely used in infant primary immunization, pediatric booster vaccination, and combination vaccine products such as DTaP-IPV, DTaP-Hib, pentavalent vaccines, and hexavalent vaccines. The upstream industry chain of Component DTP Vaccines includes suppliers of biological raw materials, antigen production technologies, vaccine adjuvants, culture media, pharmaceutical packaging materials, and manufacturing equipment. Key upstream materials include Bordetella pertussis strains for antigen production, diphtheria toxoid, tetanus toxoid, aluminum-based adjuvants, stabilizers, preservatives, cell culture materials, filtration systems, single-use bioprocessing equipment, and vaccine filling components. The production of Component DTP Vaccines requires advanced biotechnology platforms, including bacterial culture, antigen purification, detoxification, formulation, sterile filling, and quality-control processes. The midstream industry consists of vaccine manufacturers that integrate antigen production, purification technology, formulation capabilities, clinical development, regulatory compliance, and large-scale manufacturing capacity to produce finished DTP vaccine products. Leading manufacturers compete through vaccine safety performance, production capacity, regulatory approvals, combination vaccine portfolios, supply reliability, and global distribution networks. The downstream industry chain includes national immunization programs, public health agencies, hospitals, vaccination centers, pediatric clinics, and private vaccination providers. Government procurement programs represent a major demand source, particularly in countries with national childhood immunization schedules, while private vaccination markets contribute additional demand in regions where acellular vaccines are recommended or available as premium vaccine options. The Component DTP Vaccine market is expected to maintain stable growth, supported by continued demand for childhood immunization, expansion of vaccination programs in developing countries, and increasing adoption of combination vaccines that reduce the number of injections required during early childhood. The development of next-generation pertussis vaccines with improved immune durability, enhanced antigen formulations, and optimized adjuvant technologies will provide further growth opportunities. In emerging markets, improvements in healthcare infrastructure, government investment in immunization coverage, and international vaccination initiatives are expected to support market expansion. Meanwhile, developed markets will continue to focus on booster vaccination strategies, vaccine safety improvements, and advanced combination products. Although challenges such as complex manufacturing processes, strict regulatory requirements, high development costs, and competition from alternative vaccine technologies may limit market expansion, Component DTP Vaccines will remain a critical component of global immunization systems due to their established safety advantages, strong clinical acceptance, and essential role in preventing childhood infectious diseases.
    Report Scope
    This report is a detailed and comprehensive analysis for global Component DTP Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Component DTP Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Component DTP Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Component DTP Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
    Global Component DTP Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Component DTP Vaccine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Component DTP Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi Pasteur, GSK, KM Biologics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Component DTP Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market Segmentation
    Market segment by Type
    Two-component
    Multi-componen
    Market segment by Immunization Purpose
    Primary Immunization Vaccine
    Booster Immunization Vaccine
    Market segment by User
    Below 12 Months
    Above 12 Months
    Market segment by Application
    Hospital
    Clinic
    Major players covered
    Sanofi Pasteur
    GSK
    KM Biologics
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    Chapter Outline
    Chapter 1, to describe Component DTP Vaccine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Component DTP Vaccine, with price, sales quantity, revenue, and global market share of Component DTP Vaccine from 2021 to 2026.
    Chapter 3, the Component DTP Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Component DTP Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Component DTP Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Component DTP Vaccine.
    Chapter 14 and 15, to describe Component DTP Vaccine sales channel, distributors, customers, research findings and conclusion.

    Buy now